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In vivo 15N MRS has made a unique contribution to kinetic studies of the individual pathways that control
glutamate ﬂux in the rat brain. This review covers the following topics: (1) the advantages and limita-
tions of in vivo 15N MRS and its indirect detection through coupled 1H; (2) kinetic methods; (3) major
ﬁndings from our and other laboratories in the areas: (a) the uptake of the neurotransmitter glutamate
from the extracellular ﬂuid into glia; (b) the metabolism of glutamate to glutamine; (c) glutamine
transport to the extracellular ﬂuid; (d) hydrolysis of neuronal glutamine to glutamate; and (e) contri-
bution of transamination from leucine to replenish the glutamate nitrogen.
In vivo glutamine synthetase activities measured at several levels of hyperammonemia showed that
this enzyme becomes saturated at blood ammonia concentration >0.9 mmol/g, and causes the elevation
of brain ammonia. Implications of the results for the cause of hyperammonemic encephalopathy are
discussed. Leucine provides >25% of glutamate nitrogen. An intriguing possibility that supplementing
leucine may restore cognitive function after brain injury is discussed. Finally, some characteristics of 15N
MRS that may facilitate the future application of this technique to the study of the human brain at 4 or
7 T are described.
© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In vivo 15N magnetic resonance spectroscopy (MRS) is a useful
technique that has made a unique contribution to our under-
standing of metabolic ﬂux. The in vivo studies were ﬁrst performed
inmicroorganisms (reviewed by Ref. [1]) and since the 1990's in the
mammalian brain (reviewed by Refs. [2,3]).
Brain metabolites of neuropathological importance include
glutamate (GLU), which mediates most of the excitatory neuro-
transmission, and glutamine (GLN) which is closely linked tocid; BCAT, branched-chain
ransporter subtype 2; ECF,
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ri, In vivo N-15MRS study of gglutamate in the glutamine/glutamate “cycle”. Fig. 1 shows sche-
matically the major metabolic and transport pathways of GLU and
GLN in the neuron, the glia, and the extracellular compartment of
the brain. The neurotransmitter GLU (GLUNT) is released from
presynaptic vesicles in axon terminals to the extracellular ﬂuid
(ECF) and binds to the receptor of the postsynaptic neuron for
neurotransmission. It is then mainly taken up into the glia by the
excitatory amino acid transporter subtype 2 (EAAT2) and metabo-
lized to GLN by glia-speciﬁc glutamine synthetase (GS). The rapid
clearance of the glutamate in the extracellular ﬂuid (GLUECF) from
the synaptic space prevents the excessive stimulation of the GLU
receptor (GLU excitotoxicity) which is implicated in a wide range of
neurological disorders [4e6]. GLN is then transported from glia to
the extracellular ﬂuid by the sodium-coupled neutral amino acid
transporter subtype 3 (SNAT3) [7,8] and possibly by the subtype 5
(SNAT5) (Section 3.1.1). Glutamine in the extracellular ﬂuid
(GLNECF) is taken up into neurons by the sodium-coupled neutral
amino acid transporter subtypes 1 and 2 (SNAT1 and 2) [9,10].
(Corresponding earlier nomenclatures for the transporters are
given in Fig. 1 caption). Neuronal GLN is then hydrolyzed, by
phosphate-activated glutaminase (GLNase), to GLU. According to
the concept of the glutamine/glutamate cycle [11,12], this com-
pletes the recycling of GLU from GLN. An aminotransferase, viz.
branched-chain aminotransferase (BCAT), also contributes to GLUnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Major metabolic and transport pathways that contribute to glutamate ﬂux in the brain. a-KG, a-ketoglutarate; BCAT, branched-chain aminotransferase; EAAT2, excitatory
amino acid transporter subtype 2; ECF, extracellular ﬂuid; GLU, glutamate; GLUECF, GLU in the extracellular ﬂuid; GLUgl, glial GLU derived from a-KG; GLUNT, neurotransmitter GLU;
GLN, glutamine; GLNECF, GLN in the extracellular ﬂuid; GLNase, glutaminase; GS, glutamine synthetase; LEU, leucine; SNAT1,2, sodium-coupled neutral amino acid transporter
subtypes 1 and 2 (also called SAT1,2); SNAT3, subtype 3 (also called SN1).
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ﬂux of the metabolic and neurotransmitter pools of GLU and
involve the formation or transfer of amide and amine groups.
Hence, non-invasive 15N MRS makes a unique contribution to the
kinetic studies of these individual pathways in vivo.
The classical study by Berl et al. [16] which examined 15N la-
beling of brain glutamate and glutamine in 15NH4þ-infused cat led to
the important concept of compartmentation of glutamate meta-
bolism in the brain: there is a small pool that rapidly turns over that
is kinetically distinct from a larger pool that slowly turns over.
Using 13N, the positron-emitting isotope with a half-life of 10 min
that can be easily quantiﬁed, Cooper et al. measured the brain
uptake index of ammonia [17] and its incorporation into glutamine.
While the 13N studies clearly demonstrated the importance of
glutamine synthetase in the metabolism of brain ammonia, these
short-term (10e25 min) experiments did not provide a numerical
estimate of the rate of glutamine synthesis in the brain (reviewed
by Ref. [18]). Measurement of the in vivo glutamine synthetase
activity in the rat brain using 15N MRS was initiated in our labo-
ratory at 4.7 T in the 1990s and then in other laboratories at higher
ﬁeld strengths (7 and 9.4 T) (Section 3.1).
2. Methodology of 15N MRS
2.1. Characteristics of in vivo 15N MRS
The most abundant isotope of nitrogen, 14N (natural abundance
99.6%), has seldom been used for in vivo MRS because it has a
nuclear spin quantum number I ¼ 1 and hence a quadrupole
moment, leading to rapid relaxation and broad signals in most
molecules of biomedical importance. We will focus on 15N which
has a nuclear spin I ¼ ½ and provides a MRS signal with a narrow
linewidth. First, the characteristics of 15N MRS (by direct 15N
detection) that are important for in vivo studies are described.
2.2. Direct 15N detection
15N has a high spectral resolution because of its broad chemical
shift range (500e900 ppm) [19]. Its low natural-abundancePlease cite this article in press as: K. Kanamori, In vivo N-15MRS study of g
http://dx.doi.org/10.1016/j.ab.2016.08.025(0.365%) is an advantage for in vivo MRS because only those me-
tabolites that have been 15N enriched by the intravenous infusion of
a labelled precursor are normally observed, without interference
from naturally occurring 15N. This permits the measurement of the
ﬂuxes of 15N-metabolites upon a clean background. The sensitivity
of 15N is 1/1000th of that of 1H and 1/15th of that of 13C for equal
numbers of nuclei at a constant ﬁeld. However, proton-decoupling
not only removes 15N-1H splitting, but can also lead to the
enhancement of the 15N signal by the nuclear Overhauser effect
(NOE) for 15N nuclei that relax via dipolar interaction with pro-
ton(s). Due to the negative gyromagnetic ratio of 15N, the nuclear
Overhauser enhancement factor (NOEF) is negative, with a theo-
retical maximum value of 4.93. This NOEF, when added to the
original signal intensity (þ1.0), results in an inverted and enhanced
signal with a maximum NOE enhancement of 3.93 [19]. Near-
maximum NOE is observed in many molecules of biomedical
importance, such as GLU and GLN. The spin-lattice relaxation times,
T1, of these nitrogens are relatively short, < 5 s, permitting fairly
rapid signal acquisition. Consequently, 15N enriched brain metab-
olites in the 1e10mM range can be observedwith a time resolution
of 5e30 min by proton-decoupled NOE-enhanced 15N MRS in vivo
at a magnetic ﬁeld strength of 4.7 T (20 MHz for 15N) [20], 7 T [21]
and 9.4 T [22]. Demonstrated improvement in the sensitivity at
9.4 T is discussed in Section 3.1.2. In Fig. 2, the top spectrum shows
an in vivo proton-decoupled NOE-enhanced 15N spectrum of
[5-15N]GLN and [2-15N]GLU/GLN in the rat brain acquired in 19 min
during intravenous infusion of 15NH4Cl [20]. The time resolution
permits the measurement of the reaction rates on the order of
0.1e10 mmol/g/h, which comprise the in vivo rates of many key
reactions that control the ﬂux of GLU.
2.3. Indirect 15N detection through coupled 1H
The sensitivity of 15N detection is signiﬁcantly enhanced by in-
direct detection through coupled 1H by 1H-15N heteronuclear
multiple-quantum coherence (HMQC) transfer MRS [23] and het-
eronuclear single-quantum correlation (HSQC) MRS [24]. These
methods permit the selective detection of 1H spin-coupled to 15N if
the proton is non-labile at physiological pH and temperature.lutamate metabolism in the rat brain, Analytical Biochemistry (2016),
Fig. 2. In vivo 15N spectra of the rat brain, obtained with proton-decoupling and NOE-
enhancement at 20 MHz for 15N, without (top) and with (bottom) 3D ISIS localization.
Glx: GLN/GLU. In the unlocalized spectrum (top), the urea signal is strong because
[15N]urea synthesized in the liver and circulating in the blood, with a concentration of
~1.5 mM in hyperammonemia [86], enters various tissues in the head including the
brain and the facial muscle. Note that there are two 15N nuclei/urea molecule, doubling
the signal intensity. By contrast, the signals of [5-15N]Gln and [2-15N]Glx arise exclu-
sively from the brain [49] [reproduced from Ref. [3] with permission].
K. Kanamori / Analytical Biochemistry xxx (2016) 1e14 3HMQC allows the detection of low-concentration [5-15N]GLN
in vivo and [15Nindole]serotonin [25] in vitro. HSQC allows the
detection of nmol quantities of [5-15N]GLN and [15N]urea in 40 mL of
the extracellular ﬂuid [26]. Fig. 3 shows an in vivo 1H spectrum
obtained by HMQC from the rat brain [27]. Two amide protons of
[5-15N]glutamine, HZ and HE, which are coupled to 15N, are selec-
tively observed, with 15N decoupling, while all signals from protonsFig. 3. An in vivo 1H-15N HMQC spectrum of the rat brain acquired at 200 MHz for 1H,
with 15N decoupling. The amide protons of [5-15N]GLN are selectively observed. Pro-
tons not coupled to 15N are suppressed by phase-cycling [reproduced from Ref. [3]
with permission].
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http://dx.doi.org/10.1016/j.ab.2016.08.025not coupled to 15N are suppressed by phase-cycling. As an inter-
esting aside, the observation of the line-broadening of HZ, due to
base-catalyzed exchange with water proton, has provided a unique
assay of the glial pH (~7.5) in severe hyperammonemia [27],
whereas whole brain pH was unchanged in moderate hyper-
ammonemia [28] compared to that in the normal rat, which is re-
ported to be pH 7.1 (reviewed by Chesler [29]). A limitation of the
indirect detection method is that the amine protons of GLU and of
the inhibitory neurotransmitter g-aminobutyric acid (GABA)
cannot be detected at physiological pH due to their rapid exchange
with water protons. Thus, while direct 15N MRS is useful for in vivo
study of a broad range of nitrogen-containing metabolites at
1e10 mM, the indirect 1H-15N method, which has intrinsically
50e100-fold higher sensitivity, is useful for the study of low-
concentration [15N]-metabolites with non-labile protons,
including [5-15N]GLN in the extracellular ﬂuid (Section 3.3).2.4. 15N-enrichment and kinetic analysis
All animal studies performed at Huntington Medical Research
Institutes and described in this review were approved by the
Institutional Animal Care and Use Committee in accordance with
the US Public Health Service's Guide for the Care and Use of Lab-
oratory Animals.
Brain metabolites are 15N-enriched by the intravenous infusion
of 15N-labelled precursors. In all in vivo 15N MRS studies performed
so far, the i.v. infused 15N precursor is the actual substrate of the
reaction under study. 15NH3 is the substrate of glutamine synthe-
tase that forms [5-15N]glutamine (Section 3.1), of glutamate dehy-
drogenase that forms [15N]glutamate (Section 3.2), and [15N]
leucine is the substrate of transamination that forms [15N]GLU
(Section 3.5). Thus, the rate of a single reaction is measured from
the 15N enrichment of the substrate and the time-course of 15N-
product formation. This simpliﬁes kinetic analysis, and eliminates
the need to make assumptions about the rates and metabolite pool
sizes of intermediate pathways. To date, three main approaches
have been used to perform the kinetic analysis of 15N data. The ﬁrst
two, developed and used at Huntington Medical Research In-
stitutes, are shown in Fig. 4 and described below, followed by a
description of the third approach developed in other laboratories.Fig. 4. The initial rate method and the isotope chase method at steady-state. a-KIC: a-
ketoisocaproate. For other abbreviations, see Fig. 1 caption. [reproduced from Ref. [3]
with permission].
lutamatemetabolism in the rat brain, Analytical Biochemistry (2016),
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15N-labelled product, e.g. [15N]GLU in vivo [13]. The rate of
formation of total [15Nþ14N]GLU is then determined from the
rate of the initial linear increase in [15N]GLU divided by the
steady-state 15N enrichment of the substrate leucine. This
method permits accurate rate measurement when the efﬂux
of the 15N-product to other pathways is negligible.
(b) Isotope chase at steady-state. This permits accurate rate
measurement when the efﬂux rate of the product is un-
known. As shown in Fig. 4, infusion of the 15N-labelled
substrate is continued until the total concentration — that is
[14Nþ15N]— of the substrate and the product reaches steady-
state. The infusate is then changed to 14N and infusion is
continued to maintain the steady-state, while 15N is replaced
by 14N. Hence, we observe the time-course of the decrease of
the 15N-product during the replacement of 15N by 14N at the
steady state. Under this condition, it has been shown that the
rate of GLN synthesis (V1) is given by the simple equation
V1 ¼ (d([5-15N]GLN)/dt)/(ENH3 - EGLN) where d([5-15N]GLN)/
dt is the observed time-course of the decrease in [5-15N]GLN
and ENH3 and EGLN are the measured 15N enrichments of the
substrate ammonia and the product glutamine respectively.
This is described in Ref. [20] where ENH3 and EGLN were called
SA and SB respectively. This method has been used for the
measurement of the in vivo GS activity at different levels of
blood ammonia [20,30] at 4.7 T.
(c) Metabolic modeling. An alternative andmore recent approach
to determine the rate of the in vivo GS reaction in the rat
brain when the concentration of total [14N þ 15N]GLN
changes with time (i.e. at non-steady state) is to formulate
mathematical equations that govern the time-dependent
change in [5-15N]GLN in terms of the input parameters (e.g.
isotopic enrichments of the substrates and products) and an
input function (time dependent change in GLN). Next, the
rate of GS reaction is determined as the one that best ﬁts the
observed time-course of [5-15N]GLN, based on the measured
(or estimated) input parameters and the measured input
function GLN(t) [21,22]. Speciﬁc examples of this method to
measure the GS rate in hyperammonemia are described in
Section 3.1.2.2.5. Quantiﬁcation
2.5.1. [15N]metabolites
(a) Experimental measurement of the in vivo 15N peak area per
mmol of the metabolite
We quantiﬁed an 15N metabolite by experimentally measuring
the in vivo 15N peak area per mmol of the metabolite. For brain
[5-15N]glutamine, for example, we measured its in vivo peak area
per unit time as well as the actual quantity of [5-15N]GLN found in
the extract of the same brain in 10 rats. The slope of the least-
squares line through the plots provided the mean in vivo peak
area per mmol of [5-15N]GLN per g of brain. This quantity was used
to convert the observed in vivo peak area to the [5-15N]GLN con-
centration in subsequent time-course experiments [20]. The same
method was used to quantify [5-15N]GLN observed through
coupled 1H [30]. Shen et al. [21] used the same approach to quantify
brain 15N-metabolites observed by direct 15N.
(b) External reference method
Alternatively, [5-15N]GLN and [2-15N]GLU/GLN were quantiﬁedPlease cite this article in press as: K. Kanamori, In vivo N-15MRS study of g
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under identical experimental condition, from a phantom solution
containing 15N-labelled GLN and GLU, with appropriate correction
for the NOE and T1 effects [22]. This method is based on a previ-
ously described method for the quantiﬁcation of 13C data [31].
2.5.2. Total brain [15N þ 14N]metabolites
This was measured in the perchloric acid extract of the end-
point brain by enzymatic assay [20], or 1H high-resolution NMR
[21]. Recently, Cudalbu et al. [22] used a different approach by
measuring the increasing concentration of brain glutamine during
15NH4Cl infusion by in vivo 1H MRS interleaved with 15N acquisi-
tion. This is possible only at a high magnetic ﬁeld strength (9.4 T)
combined with optimum shimming that permits the resolution of
the glutamine proton peaks (H3/H4) from the adjacent glutamate
peaks (Fig. 3A of [22]).
2.5.3. Fractional enrichment
In our studies, 15N-enrichment is expressed as fractional 15N
enrichment, deﬁned as
Fractional 15N enrichment ¼
Conc: of ½15Nmetabolite  Conc: of n: a: 15N
Conc: of ½14Nþ 15Nmetabolite
where the concentration of the natural-abundance (n.a.) 15N was
calculated as 0.00365 the concentration of [14Nþ 15N]metabolite.
2.6. Localization
For the localized observation of brain 15N-metabolites, we used
image-selected in vivo spectroscopy (ISIS) developed by Ordidge
et al. [32]. In Fig. 2, the bottom spectrum shows an 15N spectrum of
[5-15N]GLN in the rat brain, acquiredwith three-dimensional ISIS in
28 min in a volume probe with a homogeneous B1 ﬁeld. An alter-
native localization method is surface-coil localization, which has
been used successfully in an 15N NMR study of the rat brain at 7 T
[21]. More recently, Cudalbu et al. [22] used a single-shot inversion
recovery based non-echo (SIRENE) sequence to obtain localized 15N
spectra from the rat brain at 9.4 T. This sequence was originally
developed for 13C MRS [33]. The effects of the ﬁeld strength and
localization methods on the signal-to-noise ratio of the brain
[5-15N]GLN are discussed in Section 3.1.2.
3. Applications
3.1. In vivo glutamine synthetase activity
3.1.1. In vivo GS activity as a function of blood [NH3] e implications
for the etiology of hyperammonemic encephalopathy
Glutamine synthetase (GS) plays an important role in protecting
the brain from several diseases. One is hepatic encephalopathy (HE)
which is a metabolic disorder of the brain caused by liver
dysfunction and by inborn errors of single genes resulting in defects
in the hepatic urea cycle (ornithine transcarbamylase deﬁciency),
reviewed, for example, by Braissant et al. [34]. The mechanisms
responsible for the pathogenesis of HE are unresolved (reviewed by
Desjardins et al. [35]). Decreased ammonia removal in the liver
causes hyperammonemia and diffusion of excess ammonia into the
brain. Ammonia is metabolized to GLN by glutamine synthetase in
glia (Fig. 1), but ammonia can accumulate if the rate of its inﬂux
exceeds the rate of its removal by GS. Whether the neurotoxicity of
ammonia itself causes encephalopathy or whether the concomitant
accumulation of GLN, which is known to cause brain edema,lutamate metabolism in the rat brain, Analytical Biochemistry (2016),
Fig. 6. Change in the brain [5-15N]GLN concentration during chase by 14N (mean ± sem
for n ¼ 5). [reproduced from Ref. [3] with permission].
K. Kanamori / Analytical Biochemistry xxx (2016) 1e14 5contributes to pathogenesis by “osmotic gliopathy” [36] has been
the subject of considerable debate [35,37].
Most early investigations of a possible correlation between the
degree of encephalopathy and brain ammonia and GLN concen-
trations in experimental animals used portacaval-shunted rats with
hepatic artery ligation [38e40]. (For a recent review on other ani-
mal models of acute and chronic liver failure, see Braissant et al.
[34]). While portacaval-shunted rats with hepatic artery ligation
are good models of acute HE, the complete loss of liver function
results in coma and death in 6e10 h, and the effects of hyper-
ammonemia are often difﬁcult to separate from the other effects of
irreversible liver failure. Hyperammonemia induced by the
administration of ammonia in rats with normal liver functions
avoids this problem and has the additional advantage that the
reversal of encephalopathy can be studied. In our study, hyper-
ammonemia was induced by the intravenous infusion of NH4Ac to
attain steady-state blood [NH3]. This permitted the examination of
the possible correlation between the severity of encephalopathy, as
assessed by neurobehavioral impairments in awake rats, and brain
ammonia and GLN concentrations. A unique feature of our study
was the measurement of the rates of glutamine synthesis in vivo at
several levels of hyperammonemia, to examine how the activity of
this enzyme controls the concentrations of brain ammonia and GLN
in vivo [41].
Fig. 5 shows the in vivo 15N spectra of the brain [5-15N]GLN
acquired during isotope chase by 14N. A progressive decrease in the
peak area is observed, as 15N is replaced by 14N while maintaining
the total (i.e. 15N þ 14N) concentration at a steady-state. Fig. 6 plots
the change in the brain [5-15N]GLN concentration during the chase.
As described in Section 2.4, the rate of glutamine synthesis was
determined from the observed time-course of [5-15N]GLN and the
15N enrichment of blood ammonia (0.077 ± 0.017), as well as that of
brain glutamine (0.24 ± 0.02), to be 4.8 ± 0.1 mmol/h/g (n ¼ 5) at a
steady-state blood NH3 concentration of 0.64 mmol/g [20]. Enrich-
ment is expressed as fractional enrichment (Section 2.5).Fig. 5. In vivo 15N spectra of the brain [5-15N]GLN before (t ¼ 0.25 h) and during
isotope chase by 14NH4þ. [reproduced from Ref. [3] with permission].
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concentration, we used the more sensitive indirect detection of 15N
through the coupled proton by HMQC transfer MRS. By combining
direct and indirect detection of [5-15N]GLN, we measured the
in vivo GS activities at ﬁve different levels of hyperammonemia,
ranging from mild to moderate to severe. As shown in Fig. 7, the
in vivo GS activity increased from 3.3 to 6.8 mmol/g/h as blood [NH3]
increased from 0.4 to 0.9 mmol/g and then reached a plateau. When
the in vivo GS activity (y) as a function of the blood NH3 concen-
tration (s) was plotted as a double-reciprocal Lineweaver-Burk plot,Fig. 7. In vivo glutamine synthetase activity (mmol/g/h) as a function of the steady-
state blood ammonia concentration, shown as the mean ± sem for n ¼ 5e8. Hyper-
ammonemia ranges from mild to moderate to severe. [reproduced from Ref. [3] with
permission].
lutamatemetabolism in the rat brain, Analytical Biochemistry (2016),
K. Kanamori / Analytical Biochemistry xxx (2016) 1e146the linear increase of 1/y with 1/s permitted the estimation of the
in vivo GS activity at the physiological blood ammonia concentra-
tion (0.17 ± 0.018 mmol/g) to be 1.3 ± 0.8 mmol/g/h [30,41]. The
plateau reached by in vivo GS activity (Fig. 7) strongly suggested
that GS becomes saturated in situ when blood [NH3] exceeds
0.9 mmol/g. Interestingly, this in vivo result is in accord with the
reported Km for ammonia of ovine brain GS, 0.18 mM [42] and the
Km for ammonia of rat liver GS, 0.3 mM [43] which can be regarded
as that of rat brain GS because of the virtually identical amino acid
sequences of the two enzymes (discussed in Kanamori et al. [20]).
The effects of the saturation of GS on brain ammonia concen-
tration and on the grade of encephalopathy observed in corre-
sponding awake rats are shown in Fig. 8. The grades of
encephalopathy, which parallel muscular incoordination pro-
gressing to stupor and coma in human HE patients [44], were
assigned according to established criteria [40]. In moderate
hyperammonemia (left ﬁgure), ammonia diffusing into the brain
was incorporated into GLN by GS and the brain ammonia concen-
tration remained at approximately 2 mmol/g during 3e8 h of
infusion. The corresponding awake rats showed only Grade III en-
cephalopathy. By contrast, in severe hyperammonemia (right
ﬁgure), brain ammonia was elevated to 3.5 mmol/g and the rats
progressed from grade III to grade IV encephalopathy (For a brief
description of Grades III and IV see Fig. 8 caption). When ammonia
infusion was stopped at t ¼ 6 h (bottom x-axis), brain ammonia
decreased and the rat recovered to grade III. This result strongly
suggests that at this level of hyperammonemia, when the in vivo GS
activity became saturated (Fig. 7), the rate of ammonia inﬂux into
the brain exceeded the rate of ammonia incorporation into GLN and
the resulting elevation of brain ammonia induced the onset of
grade IV encephalopathy.
Because GLN accumulation and the resulting brain edema have
also been implicated as a possible cause of encephalopathy [36], we
examined the brain GLN concentration as well (Fig. 9). The con-
centration was very similar in moderate and severe hyper-
ammonemia and showed little correlation with the grade ofFig. 8. Brain ammonia (mean ± sem for n ¼ 3e5) and grade of encephalopathy in moderate
move, but the righting reﬂex is present. Grade IV: motionless without the righting reﬂex.
[reproduced from Ref. [3] with permission].
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inhibited by pre-injection of L-methionine-DL-sulfoximine (MSO),
an irreversible inhibitor of GS, given intraperitoneally 4 h before the
start of NH4Ac infusion at a dose of 55 ± 5mg/kg, the brain GLNwas
only 5.5 mmol/g (open circle in the right panel of Fig. 9), but the rat
showed grade IV encephalopathy. This dose was conﬁrmed to be
non-convulsive [41]. Note that these MSO-treated rats with grade
IV encephalopathy had a brain [NH3] of 3 mmol/g (open square in
Fig. 8). These results strongly suggested that the elevation of brain
[NH3], not the accumulation of brain GLN, is the cause of enceph-
alopathy in severe hyperammonemia.
In conclusion, this study [41] resolved a controversial issue, viz
whether the neurotoxicity of ammonia itself, or the concomitant
accumulation of glutamine is the major factor in the pathogenesis
of hyperammonemic encephalopathy. This study also provided, for
the ﬁrst time, quantitative evidence for the level of hyper-
ammonemia at which GS becomes saturated, resulting in the
accumulation of neurotoxic levels of brain ammonia.
It has recently been proposed [35] that brain edema observed in
animal models of acute liver failure is caused by the trapping of
newly synthesized glutaminewithin astrocytes as a consequence of
the down-regulation of a glutamine transporter SNAT5 which has
been localized to astrocytes [45]. This proposal is based on evidence
that HE and brain edema result in a selective loss of the expression
of the gene coding for SNAT 5 in the brain [35]. Another laboratory
[46] reported a marked reduction in SNAT3 (SN1) and SNAT5 (SN2)
expression at the mRNA level and SNAT3 at the protein level, in the
cerebral cortex of rats with thioacetamide-induced HE. The
reduction coincided with marked cerebral cortex swelling in the
same model. Interestingly, SNAT3 and SNAT5 expression remained
unaltered in rats with simple hyperammonemia in the ammonium
acetate model, where the cerebral cortex volume did not change.
Taken together, the results suggest an intriguing possibility that the
restricted efﬂux of newly synthesized glutamine due to regulation
of GLN transporters contributes to brain edema in acute liver fail-
ure. However, whether SNAT5 is as widely distributed and is as(left) and severe (right) hyperammonemia. Grade III is characterized by a reluctance to
MSO: L-methionine-DL-sulfoximine, an irreversible inhibitor of glutamine synthetase.
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Fig. 9. Brain GLN (mean ± sem for n ¼ 3e5) and grade of encephalopathy in moderate (left) and severe (right) hyperammonemia. [reproduced from Ref. [3] with permission].
K. Kanamori / Analytical Biochemistry xxx (2016) 1e14 7important a mediator of GLN efﬂux in the brain as SNAT3 [7],
remain questions for future investigation [46].3.1.2. In vivo GS activities in hyperammonemia as determined by
metabolic modeling at higher magnetic ﬁeld strengths
Shen et al. [21] studied ammonia transport and glutamine
synthesis in the hyperammonemic rat brain at a plasma ammonia
concentration of 0.39 mM, using 15N MRS at 7 T and surface-coil
localization. A novel feature of their study is that the rate of
ammonia transport into the brain, Vtrans, was calculated from the
measured 15N enrichment of plasma ammonia and the initial rate of
15N incorporation into the brain [5-15N]GLN þ [2-15N]GLN/GLU to
be 0.13 ± 0.02 mmol/min/g. They proposed that the nitrogen leaving
the brain by glutamine efﬂux (Vefﬂux) should be balanced by the
rate of ammonia transport, Vtrans, and because two nitrogen atoms
leave the brain with each glutamine molecule, the relationship
Vefﬂux ¼ 0.5  Vtrans holds. The carbon moiety of glutamine lost by
the efﬂux is replaced by a-ketoglutarate synthesized (via the
tricarboxylic acid cycle) by the anaplerotic pathway. The rate of this
pathway, Vana, is known to increase under hyperammonemia.
Accordingly, it was proposed that Vefﬂux ¼ 0.5  Vtrans ¼ Vana. The
time-course of [5-15N]GLN was then expressed as
½½5 15NGlnðtÞ ¼
h
Gln
i
ðtÞfeðNH3Þplasma"
1
 ½GlnðtÞ
½Glnð0Þ
k=Vana#
where [Gln](t) ¼ [Gln](0) þ Vanat, and k ¼ VinVgln/
(Vout þ Vana þ Vgln). In this expression, Vout ¼ Vin - Vtrans and Vin is
the ammonia single-pass inﬂux rate that is equal to BUI x CBF x
[NH3]. Based on a previously reported BUI (brain uptake index) of
45% [47] and CBF (cerebral blood ﬂow) of 1.3 ml/min/g, and
measured [NH3], Vin was estimated to be approximately 0.23 mmol/
min/g. Using these input parameters and by ﬁtting the observed
in vivo [5-15N]glutamine time course to the equation above, the
rate of glutamine synthesis Vgln was determined to bePlease cite this article in press as: K. Kanamori, In vivo N-15MRS study of g
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between neurons and astrocytes) was determined from the pro-
posed relationship Vcycle ¼ Vgln e Vana, using the values of Vgln
determined above and of Vana ¼ 0.5  Vtrans determined from the
value of V trans.
More recently, Cudalbu et al. [22] studied brain glutamine
metabolism in hyperammonemia in vivo by localized 1H and 15N
MRS spectroscopy at 9.4 T. For 15N acquisition, they used amodiﬁed
pulse sequence consisting of two adiabatic half-passage pulses to
excite [5-15N]GLN and [2-15N]GLU/GLN separately in a single in vivo
experiment. The higher magnetic ﬁeld strength, combined with
shimming using the echo planar version of the “fast automatic
shimming technique by mapping along projections” (FASTMAP)
[48], resulted in an improved signal-to-noise ratio of the in vivo
[5-15N]GLN peak, as seen from a comparison of the peak acquired in
30 min in Fig. 1b of Kanamori et al. [20] at 4.7 T with that acquired
in 25min in Fig. 4C of Cudalbu et al. [22]. Their localization method,
single-shot inversion recovery based non-echo sequence (Section
2.6), is also an improvement over ISIS localization with a volume
coil (Fig. 2 bottom). It is encouraging that for the observation of
brain [5-15N]glutamine in vivo, there were only very small differ-
ences in the peak areas between non-localized and localized
spectra, suggesting that almost the entire [5-15N]GLN signal comes
from the brain and not from surrounding tissues, as noted by
Cudalbu et al. [22]. This is a point that was investigated earlier by
in vitro measurements of [5-15N]GLN in the brain and adjacent
muscle tissues by Kanamori et al. [49] before initiating the in vivo
15N studies of the rat brain.
For the calculation of the in vivo GS rate, the metabolic model of
Cudalbu et al. [22] is simpler in that only the ﬂux of nitrogen is
considered. Glutamine efﬂux from the brain to the blood was
considered to be negligibly small based on previous studies [20,41],
and so was the ﬂow of 15N to aspartate based on their experimental
observation. For the measurement of the rate of glutamine syn-
thesis, the time-course of the total GLN measured by 1H MRS and
that of [5-15N]GLN measured by 15N MRS were used as experi-
mental data. The time course of [5-15N]GLN was expressed (eq. (15)
in Cudalbu et al. [22]) aslutamatemetabolism in the rat brain, Analytical Biochemistry (2016),
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 Vnt
ðVin þ VntÞ  Vsyn
ðVin þ VntÞ
 ½5 15NGln
½Glnð0Þ þ Vsyn  Vntt
where Vnt is deﬁned by these authors as the apparent rate of
neurotransmission, and corresponds to the rate of cycling of GLU
and GLN between neurons and astrocytes (Vcycle of Shen et al. [21]),
and Vin is the ammonia single-pass inﬂux rate for which they used
the value of 0.23 mmol/g/min reported previously [17,21,50]. The
linear ﬁt of the time evolution of the total Gln (Fig. 5A of Cudalbu
et al. [22]) provided a measure of the net glutamine accumulation
(Vsyn- Vnt), to be 0.033 ± 0.001 mmol/g/min and the initial Gln
concentration (Gln(0)) to be 2.3 mmol/g. With these input param-
eters and function applied to the equation above, the rate of GLN
synthesis, Vsyn, was determined from the best ﬁt to the observed
time-course of [5-15N]GLN, to be 0.30 ± 0.05 mmol/g/min. Finally,
Vnt was determined, from these values of Vsyn and Vsyn-
Vnt ¼ 0.033 mmol/g/min, to be 0.26 ± 0.03 mmol/g/min.
3.1.2.1. Comparison of the kinetic methods - isotope chase at steady-
state vs metabolic modeling at non-steady state. The method of
isotope chase at steady-state requires fewer assumptions because
in addition to the non-invasive MRS observation of the time-course
of [5-15N]GLN, the steady-state concentrations of all substrates/
products as well as the 15N enrichment of the substrate blood NH3
are experimentally measured by conventional biochemical
methods. This provides an opportunity to compare these experi-
mental values (e.g. total [GLN] at various levels of hyper-
ammonemia) with those reported previously from other
laboratories. Thus, the method of isotope chase at steady-state re-
quires more time. The work by Cudalbu et al. [22], using a simple
metabolic model, determined the rate of glutamine synthesis, Vsyn,
and the rate of net glutamine accumulation, Vsyn e Vnt,, from 15N
and 1H data respectively in a single elegant experiment. Because
metabolic modeling provides an opportunity to examine how
variations in an input parameter or function affect the calculated
rate of Vgln, it would have been informative if the effect of varying
[GLN](0) on GLNsyn had been reported. [Gln](0) of 2.3 mmol/g before
ammonia infusion is lower than most previous reports of GLN
concentration in the normal rat brain (4.3e6.5 mmol/g) [40,51e53].
In summary, in comparing the rates of in vivo GS activities in
hyperammonemia reported from the three laboratories to date, it is
important to discern the underlying assumptions in each method
and, where possible, complement in vivo MRS data with conven-
tional biochemical assays, as this is feasible in animal brain.
3.2. In vivo glutamate dehydrogenase activity
Glutamate dehydrogenase (GDH) catalyzes the reversible
reaction:
NH3 þ 2-oxoglutarate þ NAD(P)H4 glutamate þ NAD(P)þ
The in vivo activity of glutamate dehydrogenase (GDH) in the
direction of reductive amination was measured in the rat brain at
steady-state concentrations of brain ammonia and glutamate after
the intravenous infusion of the substrate 15NH4þ, using 15N NMR
[54]. The in vivo rate was determined from the steady-state frac-
tional 15N enrichment of brain ammonia, and the rate of the in-
crease of brain [2-15N]glutamate/glutamine observed by 15N NMR
at 4.7 T. The in vivo GDH activity was 0.76e1.17 mmol/g/h, (corre-
sponding to 0.013e0.02 mmol/g/min) at an 15NH4Cl infusion rate ofPlease cite this article in press as: K. Kanamori, In vivo N-15MRS study of g
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an 15NH4Cl infusion rate of 3.3 mmol/g/h. Recently, Cudalbu et al.
[22] used the new 15N adiabatic pulse sequence to excite the amine
nitrogens separately from the amide nitrogen (Section 3.1.2) in a
single experiment to measure GDH activity (in addition to GS ac-
tivity) at 9.4 T. In their metabolic model, GDH was considered to be
mainly in astrocytes, on the basis of measured 15N enrichment ratio
of ([2-15N]Gln)FE/([2-15N]Glu)FE ¼ 1.48 ± 0.04. The time-course of
in vivo [2-15N]GLN/GLU was ﬁtted to mathematical equations (Eqs.
(18), (19) and (23) in Cudalbu et al. [22]) to obtain GDH rate of
0.029 ± 0.002 mmol/g per min at an 15NH4Cl infusion rate of
4.5 mmol/g/h. The results from the two laboratories are in good
agreement when the difference in the ammonia infusion rates is
considered. The low in vivo activity compared to the reported
in vitro activity of GDH measured at enzyme-saturating concen-
trations of the substrates, 900 mmol/g/h [55], can most reasonably
be attributed to the low in situ concentrations of ammonia and of 2-
oxoglutarate (0.23 ± 0.05 mM) [40,52,54] relative to the Km values
of the enzyme, 10e18 mM for NH4þ and 0.2e1.5 mM for 2-
oxoglutarate [56,57]. The two MRS studies strongly suggest that
there is net GDH-catalyzed glutamate synthesis from ammonia in
hyperammonemic brain, although the rate is slow. In the study by
Cudalbu et al. [22], the reverse component of GDH, oxidative
deamination of GLU, converged to zero, suggesting that it is
negligible. How to reconcile these ﬁndings with the prevalent view
that the direction of the GDH reaction in the brain in vivo is mainly
towards glutamate catabolism [58] is an area for future
investigation.
3.3. Regulation of the GLN transport from glia to the ECF
In the glutamine/glutamate cycle, the pathway that had been
the least well-understood was the mechanism of GLN transport
from the glia, through the extracellular ﬂuid (ECF), to the neuron
(Fig. 1). The identiﬁcation and characterization of GLN transporters,
SNAT3 [7] and SNAT1 [9] and SNAT2 [10] have signiﬁcantly
advanced our understanding of the transport mechanism. The
current view of GLN transport in the adult brain is of GLN release
from glia mainly mediated by the system N transporter, SNAT3, and
of GLN uptake into neurons mainly mediated by system A trans-
porters, SNAT1 and SNAT2 (reviewed by Br€oer et al. [59]).
SNAT3 mediates the co-transport of GLN with Naþ in exchange
for Hþ [7,8]. In vitro, the transport is bi-directional and the direction
of transport (inﬂux or efﬂux) depends on the magnitudes of the
driving forces [7]. A large transmembrane GLN gradient is expected
to induce efﬂux despite the large inwardly directed driving force for
Naþ and the outwardly directed force for Hþ that would both tend
to prevent efﬂux. These investigators proposed, based on in vitro
studies, that extracellular GLN less than 0.4 mM induces GLN efﬂux.
The GLN concentration in the ECF of the normal rat brain,
measured by the zero-ﬂow method [60], is 0.385 ± 0.016 mM [61].
Alexander et al. [62] provided an estimate of 0.262 ± 0.012 mM for
GLNECF concentration in the rat cortex. Whole-brain [GLN], repre-
senting predominantly intracellular GLN, is ~8 mM [51]. At least
80% of intracellular GLN is estimated to be in glia based on
immunocytochemical studies [63,64] also see Ref. [27]. Therefore, a
reasonable estimate for the GLN gradient across the glial plasma
membrane is 17 (¼6.4 mM/0.385 mM).
In view of the importance of glia-to-neuron GLN transport in the
glutamine/glutamate cycle, we examined the transport character-
istics of SNAT3 in vivo, which had not been attempted previously.
We investigated the effect of the transmembrane GLN gradient on
the rate of glial GLN release through themeasurement of (a) GLNECF
collected by microdialysis, (b) the transmembrane GLN gradient
and (c) the time-course of intracellular glial [5-15N]GLN by 15NMRSlutamate metabolism in the rat brain, Analytical Biochemistry (2016),
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during i.v. infusion of 14NH4Ac for 3 h to achieve steady-state glial
[GLN], followed by 15NH4Ac infusion to 15N-enrich brain GLN [26].
As shown in Fig. 10, GLNECF increased gradually for 4 h, then
showed a sharp increase at t ¼ 4.5 h of NH4Ac infusion. An inter-
esting possibility is that this elevation was caused by the accumu-
lation of GLNECF when its neuronal uptake mediated by SNAT1
(with a Km of 0.3e0.49 mM in vitro [9,65]) became saturated. The
[GLN]i/[GLN]ECF ratio was 9.6 ± 0.9 [26], which is signiﬁcantly lower
than the ratio of ~17 in the normal brain. GLNECF then decreased
substantially at t ¼ 4.9 ± 0.1 h. To investigate whether this decrease
reﬂects the reduction of glial GLN efﬂux due to a decrease in the
transmembrane GLN gradient, we compared the time-courses of
intracellular and extracellular [5-15N]GLN during this period. As
shown in Fig. 11a, intracellular, predominantly glial, [5-15N]GLN
increased progressively. By contrast, extracellular [5-15N]GLN
reached a plateau after T¼ 1.9 h of 15NH4Ac infusion (Fig. 11b upper
x-axis), which corresponds to t ¼ 4.9 h of [14Nþ15N]ammonia
infusion (lower x-axis). These results strongly suggest that the
efﬂux of glial [5-15N]GLN to ECF was reduced at this time, corre-
sponding to a total NH4Ac infusion time of 4.9 ± 0.1 h when GLNECF
decreased substantially (Fig. 10). Taken together, these results
strongly suggest that when the transmembrane GLN gradient
decreased to 9.6 ± 0.9, the driving force for GLN efﬂux was weak-
ened, resulting in suppression of glial GLN release to ECF in vivo.
Other possible causes for the observed decrease in GLNECF, such as
osmotic disturbance and a change in the Naþ gradient, have been
examined and ruled out.
The partial suppression of glial GLN efﬂux to ECF when GLNECF is
elevated prevents excessive release, when its neuronal uptake by
SNAT1 and SNAT2 has reached saturation and the rate of the glia-
to-neuron transport of GLN cannot be further increased. This sug-
gests that the bi-directional nature of SNAT3 permits ﬁne control of
the rate of glial GLN efﬂux to ECF.
In conclusion, this study showed for the ﬁrst time that (a) the
combination of 15N MRS to monitor glial intracellular [5-15N]GLN
and microdialysis/1H-15N HSQC to monitor extracellular [5-15N]
GLN permits the study of how the GLN transporter SNAT3 operates
in vivo and (b) the trans-membrane GLN gradient plays a key role in
controlling glial GLN efﬂux to ECF at physiological Naþ gradient.Fig. 10. Dialysate GLN as % of the basal conc (the left coordinate) and the extracellular
GLN concentration (mM) (the right coordinate) during NH4Ac infusion (mean ± sem
for n ¼ 5). The mean extracellular GLN concentration at t ¼ 5.0 h (shown by *) is
signiﬁcantly different from that at t ¼ 4.5 h (p < 0.01). [reproduced from Ref. [3] with
permission].
Fig. 11. (a) Time-course of intracellular [5- N]GLN (mean ± sem for n ¼ 4) measured
by 15N MRS. 15NH4Ac infusion was started after 3 h of 14NH4Ac infusion. Note that the
total [14N þ 15N]GLN was at steady-state during this period (Fig. 3b of [26]). (b) The
time course of extracellular [5-15N]GLN (mean ± sem for n ¼ 5). The inset shows the
1H-15N HSQC spectrum of extracellular [5-15N]GLN (9.7 nmol in 40 mL of dialysate)
obtained at 600 MHz [reproduced from Ref. [3] with permission].
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GLN released to ECF by SNAT3 is taken up into neurons mainly
by SNAT1 and SNAT2 and hydrolyzed by glutaminase (GLNase) to
GLU. The in vivo rate of the GLNase pathway, as measured by 15N
MRS at blood ammonia concentration of 0.4 mmol/g, was
1.1 ± 0.2 mmol/g/h [66].3.5. Rate of glutamate synthesis from leucine
Another pathway that can contribute to GLU synthesis by
replenishment of its nitrogen is the transamination from leucine
(LEU) to a-ketoglutarate to form GLU. The amine groups of aspar-
tate and alanine, although these metabolites are present at higher
concentrations in the brain than leucine, are in rapid exchangewith
the amine group of glutamate [51] [58] and do not contribute to de
novo GLU synthesis because plasma aspartate and alanine have
very low rates of uptake into the brain. By contrast, the essentiallutamatemetabolism in the rat brain, Analytical Biochemistry (2016),
Fig. 13. Increase in brain [15N]GLU during [15N]LEU infusion. (mean ± sem for n ¼ 5).
Filled circle: anesthetized rats; open triangle: awake rats. [reproduced from Ref. [3]
with permission].
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has a very high brain uptake index. In the brain, branched-chain
aminotransferase (BCAT) catalyzes the transfer of the amine
group from LEU to a-ketoglutarate to form GLU (Fig. 1). Studies in
cultured astrocytes, neurons and synaptosomes showed LEU to be a
good source of GLU nitrogen ([67] and references cited therein), but
its role in the intact brain was unknown. To evaluate possible
contribution of LEU as a source of GLU nitrogen, we measured the
rate of GLU synthesis from LEU in the rat brain in vivo by 15N NMR
[13].
Awake rats were fed exclusively by the intravenous infusion of
glucose, amino acids (including LEU) and minerals and vitamins for
two days. By the third day, all of the plasma and brain amino acids
were at a steady-state and the brain GLU concentrationwas normal.
[14N]LEU was then replaced by [15N]LEU and the rate of GLU syn-
thesis from LEUwasmonitored in vivo. Fig.12 shows representative
in vivo 15N spectra of the rat brain during [15N]LEU infusionwhere a
progressive increase in brain [15N]GLU was observed. Fig. 13 shows
the increase in brain [15N]GLU concentration, determined from the
complete set of sixteen in vivo time course spectra acquired from
anesthetized rats. Also shown are the concentrations determined at
several time points in brain extracts from rats that were awake
during [15N]LEU infusion. These agreedwell with theMRS data. The
rate of [15N]GLU synthesis in vivo was determined from the slope of
the least-squares line during the initial linear increase to be
0.34 ± 0.01 mmol/g/h. From this rate and the observed 15N enrich-
ments of brain and blood LEU, the rate of GLU synthesis from LEUFig. 12. Representative in vivo 15N spectra of brain [15N]GLU during [15N]LEU infusion.
[reproduced from Ref. [3] with permission].
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brain LEU concentration of 0.235 mmol/g (S2). This concentration
ensures that the observed rate of synthesis was not limited by the
rate of LEU transport into the brain. At the physiological brain LEU
concentration (S1) of 0.11 mmol/g, the in vivo rate (V1) was esti-
mated from the Michaelis-Menten equation, V2/V1 ¼ S2[Km þ S1]/
S1[Km þ S2], the observed values of V2 and S2 and the known Km
(1.2 mM) of BCAT for LEU [68], to be 0.35e0.9 mmol/g/h, with LEU
providing ~25% of glutamate nitrogen. Subsequently, Sakai et al.
[15] fed [U-13C]leucine and/or [15N]leucine in awake rats for up to
9 h and examined the time-courses of the 15N and 13C enrichments
of brain GLU and other amino acids at several time points during
this period (Fig. 1 in Sakai et al. [15]). Kinetic analyses showed that,
at the physiological brain leucine concentration, leucine nitrogen
provides ~50% of brain glutamate nitrogen. Taken together, the
results from the two laboratories clearly show that plasma leucine
entering the brain is an important source of glutamate nitrogen.
As described by Hall et al. [68], the branched-chain amino-
transferase has two isoforms, the mitochondrial BCATm and the
cytosolic BCATc which represents 70% of the total BCAT activity in
the brain. At the time of the enrichment studies described above,
the distribution of BCAT in brain cell types (neuron vs glia) was
unknown. Subsequent immunohistochemical studies showed a
widespread expression of BCATc in the cell bodies and axon ter-
minals of glutamatergic and other types of neurons in the rat [14]
and, more recently, in the human brain [69,70], while BCATm is
localized to astrocytes [71]. Taken together, the results strongly
suggest that BCATc-catalyzed transamination from LEU makes a
signiﬁcant contribution to the replenishment of neuronal GLU,
which consists of metabolic and neurotransmitter pools.
As mentioned by Cole et al. [71], there was a signiﬁcant reduc-
tion in the concentrations of the branched-chain amino acids
(BCAAs) in the hippocampus (as well as a decrease in BCATc) after
brain injury in mice, that was associated with cognitive impair-
ment. Interestingly, supplementing BCAAs in the drinking water
completely restored the hippocampal BCAA concentrations and
cognitive performance [72]. Importantly, similar results were
shown in clinical trials with humans; administration of IV boluseslutamate metabolism in the rat brain, Analytical Biochemistry (2016),
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amelioration of their cognitive states [73,74]. These results, com-
bined with the demonstrated role of leucine as a provider of GLU
nitrogen in vivo, suggest an intriguing possibility that the depri-
vation of hippocampal BCAAs is associated with a reduction in the
excitatory neurotransmitter GLU that leads to cognitive impair-
ment, and that supplementing dietary amino acid leucine may help
towards recovery of cognitive function.3.6. Glial uptake of the neurotransmitter GLU
Metabolic GLU is taken up by a uni-directional transporter into
presynaptic vesicles to form the neurotransmitter pool of GLU
(Fig. 1). It is released by exocytosis into synaptic ﬂuid, binds to the
receptor and is rapidly taken up mainly into glia and is metabolized
to GLN. We have taken the novel approach of taking into account
the vesicular neurotransmitter pool of GLU in addition to its
metabolic pools. We have used a combination of (a) in vivo 13C/15N
MRS to examine the enrichment time-courses of intracellular GLU/
GLN and (b) microdialysis and gas-chromatography mass-spec-
trometry to monitor the enrichment time course of extracellular
GLU [75]. Glial uptake of the neurotransmitter [5-13C]GLUECF was
monitored in vivo through the formation of [5-13C,15N]GLN during
15NH4Ac infusion. From the rate of [5-13C,15N]GLN synthesis
(1.7 ± 0.03 mmol/g/h), themean 13C enrichment of extracellular GLU
(0.304 ± 0.011) and the 15N enrichment of precursor NH3
(0.87 ± 0.014), the rate of synthesis of GLN (V’GLN), derived from the
neurotransmitter GLUECF, was determined to be 6.4 ± 0.44 mmol/g/
h. In an earlier 15N NMR study, we determined the rate of synthesis
of glutamine to be 6.8 ± 0.7 mmol/g/h under identical experimental
conditions [41]. This glutamine is synthesized from the metabolic
glial GLU pool þ neurotransmitter GLU taken up into glia (Fig. 1).
Comparison of the two rates strongly suggested that the neuro-
transmitter GLU provides 80e90% of the substrate GLU pool for GLN
synthesis.Fig. 14. In vivo rates (mmol/g/h) of the major pathways that control the ﬂux
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4.1. In vivo ﬂuxes of the major pathways of GLU synthesis
Fig. 14 summarizes the in vivo rates of the major pathways that
contribute to the synthesis and utilization of GLU, as measured in
spontaneously-breathing rats by non-invasive 15N and/or 1H-15N
HMQC MRS. Neurotransmitter GLU, taken up into glia, is the major
source of substrate GLU for GLN synthesis. The in vivo rate of
glutamine synthesis, catalyzed by glia-speciﬁc glutamine synthe-
tase, is estimated to be 1.3 ± 0.8 mmol/g/h under physiological
condition, while the rate of GLN hydrolysis to GLU, catalyzed by
glutaminase that is mainly present in the neuron, is 1.1 ± 0.2 mmol/
g/h. These ﬂuxes through the glutamine/glutamate cycle are higher
than the rate of GLU synthesis from LEU catalyzed by branched-
chain aminotransferase (0.35e0.9 mmol/g/h). These results sug-
gest that approximately 75% of brain GLU is recycled from GLN in
the glutamine/glutamate cycle, while LEU provides approximately
25% of neuronal GLU nitrogen. Clearly, multiple pathways
contribute to the ﬂux of GLU in the intact brain. We hope that our
studies focusing on the in vivo rates of speciﬁc pathways
contribute, in combination with studies from other laboratories, to
a clearer understanding of the complex mechanisms that regulate
the ﬂux of the neurotransmitter andmetabolic pools of GLU in vivo.4.2. Future perspectives
4.2.1. Animal brain
The sensitivity of detection of 15N-metabolites in the rat brain
has been shown to improve with the increase in ﬁeld strength from
4.7 T used in our studies to 9.4 T [22] (Section 3.1.2). This is
promising because an animal scanner of even higher ﬁeld strength,
14.1 T, is now available, as described in “MRS studies of neuro-
energetics and glutamate/glutamine exchange in rats: extensions
to hyperammonemic models” by Dr. B. Lanz et al., published in this
special issue. Sensitivity enhancement of 15N by hyperpolarization
and the feasibility of detecting hyperpolarized 15N-choline in theof glutamate in the brain. [reproduced from Ref. [3] with permission].
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K. Kanamori / Analytical Biochemistry xxx (2016) 1e1412rat are described in “Hyperpolarized MRS: new tool to study real-
time brain function and metabolism” by Dr. M. Mishkovsky et al.,
published in this special issue.
Signiﬁcant advances have been made in the design of RF coils,
pulse-sequences and localization techniques for 13C MRS, as
described elsewhere in this issue. As discussed in this chapter, some
have already been adapted to 15N, which is less sensitive, but also
less ubiquitous. These two features ensure (a) virtual absence of
interference from natural abundance 15N and (b) well-resolved
spectra of 15N-enriched metabolites in vivo. Furthermore, signiﬁ-
cant advances have been made in the immunocytochemical local-
izations of enzymes and transporters that control glutamate
metabolism in the neuronal, glial and extracellular compartments,
as described throughout this chapter. For the analyses of extracel-
lular glutamate involved in neurotransmission and of extracellular
glutamine as source of neuronal glutamate, a useful approach is to
combine the 13C or 15N enrichment time-course of intracellular GLU
or GLN observed by in vivo MRS with the 13C or 15N enrichment
time-course of extracellular GLU or GLN, collected in vivo by
microdialysis from the rat brain, followed by in vitro analyses using
sensitive mass-spectrometry [76] or 1H-15N HSQC (Section 3.3).
Thus, a potentially productive area for future research is to explore
the complex pathways, involving less abundant neurochemicals,
that control glutamate metabolism and its role in neurotransmis-
sion in the heterogeneous brain.
4.2.2. Potential for clinical study
How feasible is it to extend conventional 15NMRS to the study of
human brain? The following considerations are encouraging. A
dramatic gain in sensitivity is expectedwhen the volume of interest
(VOI) is increased from <2.3 ml for the rat brain to, for example,
72 ml [77], 144 ml [78,79] or 210 ml [80] of the human brain used
for in vivo 13C MRS at 2.1 or 4 T. At present, administration of an
15N-labelled precursor is likely to be essential for an in vivo 15N
MRS study of the human brain. [15N]leucine, an essential amino
acid that can safely be given intravenously, or as food supplement,
is a promising candidate. As described in Section 3.5, the important
roles of leucine in replenishing glutamate nitrogen [13,15], and in
the restoration of cognitive function after brain injury in mice [72]
have been demonstrated. In view of the recent advances in the
characterization of BCAT in the human brain [69] and the encour-
aging outcome after the administration of branched-chain amino
acids to brain-injured patients [74], non-invasive studies of brain
GLU after administration of the labelled leucine to explore its
therapeutic potential may be a promising area for future
investigation.
Despite the improvements in sensitivity at high magnetic ﬁeld,
the main limitation in human studies is the power deposition in
tissue by radiofrequency pulses, especially when using 1H-decou-
pling (see for example [81,82]). However, power deposition for the
proton-decoupling of 15N is expected to be lower than the level
successfully used in clinical 13C MRS because typical one-bond
1H-15N coupling (e.g. ~ 90 Hz in GLN amide) is smaller than the
one-bond 1H-13C coupling (e.g. ~130 Hz in GLU C4). Another
encouraging characteristic of 15N is that for amine nitrogens of
glutamate, glutamine and GABA (though not for the amide nitrogen
of GLN), proton decoupling is not essential because the amine
protons exchange rapidly with water protons at physiological pH,
and, consequently, these amine nitrogens observed in vivo are
virtual singlets without proton decoupling. Studies in the 1970s by
the pioneers of high-resolution 15N NMR showed that for amine
nitrogens of amino acids, 1JN-H of ~74 Hz collapses due to rapid
exchange with water protons at physiological pH [83], 2J N-C-H is
very small (0.1e1.5 Hz: Table 146, p.413 in Ref. [84]) and 3J N-C-C-Hb is
2.9 Hz [83]. Signal enhancement by NOE [85] which is nearly 4-foldPlease cite this article in press as: K. Kanamori, In vivo N-15MRS study of g
http://dx.doi.org/10.1016/j.ab.2016.08.025in the amine nitrogens [83] (Section 2.1) is still desirable for
sensitivity enhancement, but the power required to generate NOE
is signiﬁcantly lower than that for proton-decoupling when the
WALTZ (Waugh-Levitz)16 bi-level decoupling sequence is used. For
example, the required power was 0.25 W for NOE and 6 W for
proton-decoupling in our in vivo experiment [20]. Furthermore, the
radiofrequency power required to achieve a large bandwidth can be
reduced if we focus, for example, on detection of the amine nitro-
gens of the excitatory neurotransmitter GLU and of the inhibitory
neurotransmitter GABA, because GABA nitrogen, although well
resolved from the a nitrogens of GLU/GLN, at ~6 ppm upﬁeld [84]
resonates in the same 340 to 348 ppm region, permitting se-
lective excitation. Finally, ongoing improvement in the design of
1H-13C coil (e.g. Ref. [81]) that achieves a 1.4 fold enhancement in
sensitivity without an increase in the power deposition for clinical
proton-decoupled 13C MRS at 7 T, may eventually be adapted for
clinical 15N studies. We hope that these considerations may be
useful in designing well-focused clinical in vivo 15N MRS studies in
the future.
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